MA29082B1 - Composes de pyridine destines au traitement de maladies a mediation par prostaglandine - Google Patents
Composes de pyridine destines au traitement de maladies a mediation par prostaglandineInfo
- Publication number
- MA29082B1 MA29082B1 MA29966A MA29966A MA29082B1 MA 29082 B1 MA29082 B1 MA 29082B1 MA 29966 A MA29966 A MA 29966A MA 29966 A MA29966 A MA 29966A MA 29082 B1 MA29082 B1 MA 29082B1
- Authority
- MA
- Morocco
- Prior art keywords
- prostaglandin
- treatment
- mediated diseases
- pyridine compounds
- pyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0428263A GB0428263D0 (en) | 2004-12-23 | 2004-12-23 | Compounds |
GB0508458A GB0508458D0 (en) | 2005-04-26 | 2005-04-26 | Compounds |
GB0524675A GB0524675D0 (en) | 2005-12-02 | 2005-12-02 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29082B1 true MA29082B1 (fr) | 2007-12-03 |
Family
ID=35735391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA29966A MA29082B1 (fr) | 2004-12-23 | 2007-06-06 | Composes de pyridine destines au traitement de maladies a mediation par prostaglandine |
Country Status (20)
Country | Link |
---|---|
US (2) | US20100137378A1 (fr) |
EP (2) | EP1833795B1 (fr) |
JP (1) | JP2008525363A (fr) |
KR (1) | KR20070091301A (fr) |
AR (1) | AR052429A1 (fr) |
AT (1) | ATE424386T1 (fr) |
AU (1) | AU2005318372A1 (fr) |
BR (1) | BRPI0519398A2 (fr) |
CA (1) | CA2592442A1 (fr) |
DE (1) | DE602005013116D1 (fr) |
EA (2) | EA200801909A1 (fr) |
ES (1) | ES2321535T3 (fr) |
IL (1) | IL183781A0 (fr) |
MA (1) | MA29082B1 (fr) |
MX (1) | MX2007007830A (fr) |
NO (1) | NO20073332L (fr) |
PE (2) | PE20060838A1 (fr) |
TW (1) | TW200640865A (fr) |
UY (1) | UY29298A1 (fr) |
WO (1) | WO2006066968A1 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0608825D0 (en) * | 2006-05-04 | 2006-06-14 | Glaxo Group Ltd | Compounds |
CA2687764A1 (fr) * | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Modulateurs de canal ionique et leurs procedes d'utilisation |
FR2921062A1 (fr) | 2007-09-17 | 2009-03-20 | Commissariat Energie Atomique | Composes utiles comme ligands et notamment comme chromophores organiques de complexation des lanthanides et leurs applications |
US8399436B2 (en) | 2009-04-24 | 2013-03-19 | Glaxo Group Limited | N-pyrazolyl carboxamides as CRAC channel inhibitors |
KR20120038544A (ko) | 2009-07-31 | 2012-04-23 | 판미라 파마슈티칼스, 엘엘씨 | Dp2 수용체 길항제의 안과용 약학 조성물 |
WO2011017201A2 (fr) | 2009-08-05 | 2011-02-10 | Amira Pharmaceuticals, Inc. | Antagoniste de dp2 et ses utilisations |
WO2012052459A1 (fr) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Composés de pyrazole agissant contre des troubles allergiques, inflammatoires et immunitaires |
EP2570125A1 (fr) * | 2011-09-16 | 2013-03-20 | Almirall, S.A. | Ligands du récepteur Ep1 |
EP3152199B1 (fr) | 2014-06-03 | 2018-08-15 | Idorsia Pharmaceuticals Ltd | Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t |
AU2015328174B2 (en) | 2014-10-06 | 2020-05-21 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2017173274A1 (fr) | 2016-03-31 | 2017-10-05 | Vertex Pharmaceuticals Incorporated | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique |
DK3519401T3 (da) | 2016-09-30 | 2021-11-22 | Vertex Pharma | Modulator af cystisk fibrosetransmembrankonduktansregulator, farmaceutiske sammensætninger, fremgangsmåder til behandling og fremgangsmåde til fremstilling af modulatoren |
AU2017371200B2 (en) | 2016-12-09 | 2021-05-06 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
EA201991428A1 (ru) | 2016-12-16 | 2019-12-30 | Идорсия Фармасьютиклз Лтд | Фармацевтическая комбинация, содержащая блокатор кальциевых каналов т-типа |
CN110234622B (zh) | 2017-02-06 | 2023-07-04 | 爱杜西亚药品有限公司 | 用于合成1-芳基-1-三氟甲基环丙烷的新颖方法 |
US11253509B2 (en) | 2017-06-08 | 2022-02-22 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2019018395A1 (fr) | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | Méthodes de traitement de la fibrose kystique |
MA49752A (fr) | 2017-08-02 | 2021-04-21 | Vertex Pharma | Procédés de préparation de composés de pyrrolidine |
WO2019079760A1 (fr) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Formes cristallines et compositions de modulateurs de cftr |
MA51039A (fr) | 2017-12-08 | 2020-10-14 | Vertex Pharma | Procédés pour préparer des modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1471276A (en) | 1975-01-22 | 1977-04-21 | Nippon Shinyaku Co Ltd | 5-benzylpicolinic acid deri vatives |
EP0388682A1 (fr) | 1989-03-15 | 1990-09-26 | Bayer Ag | Hétéroarylphényléthers substitués, procédés pour leur préparation et leur utilisation comme insecticides |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
AU1441195A (en) | 1993-12-30 | 1995-07-17 | Smithkline Beecham Corporation | Phenylmethyl hexanamides, and the use thereof |
GB9514160D0 (en) | 1994-07-25 | 1995-09-13 | Zeneca Ltd | Aromatic compounds |
GB9417532D0 (en) | 1994-08-31 | 1994-10-19 | Zeneca Ltd | Aromatic compounds |
GB9420557D0 (en) * | 1994-10-12 | 1994-11-30 | Zeneca Ltd | Aromatic compounds |
AU4515696A (en) | 1994-12-12 | 1996-07-03 | Merck & Co., Inc. | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase |
EP0809636B1 (fr) | 1995-02-13 | 2002-09-04 | G.D. Searle & Co. | Isoxazoles substitues utilisables dans le traitement d'inflammations |
US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
TW434240B (en) | 1995-06-20 | 2001-05-16 | Zeneca Ltd | Aromatic compounds, preparation thereof and pharmaceutical composition comprising same |
TW502026B (en) | 1995-06-20 | 2002-09-11 | Zeneca Ltd | Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates |
US5834468A (en) | 1995-07-07 | 1998-11-10 | Zeneca Limited | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists |
UA57002C2 (uk) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування |
ES2311571T3 (es) | 1996-04-12 | 2009-02-16 | G.D. Searle Llc | Derivados de bencenosulfonamida sustituidos como profarmacos de inhibidores de cox-2. |
PT912518E (pt) | 1996-07-18 | 2003-12-31 | Merck Frosst Canada Inc | Piridinas substituidas como inibidores selectivos de ciclooxigenase-2 |
CO4960662A1 (es) | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
CA2303152A1 (fr) | 1997-09-05 | 1999-03-18 | Glaxo Group Limited | Derives de 2,3-diaryl-pyrazolo[1,5-b]pyridazine, leur preparation et leur utilisation en tant qu'inhibiteurs de cyclooxygenase 2 (cox-2) |
US6362009B1 (en) * | 1997-11-21 | 2002-03-26 | Merck & Co., Inc. | Solid phase synthesis of heterocycles |
US6605624B1 (en) | 1998-02-13 | 2003-08-12 | Pharmacia Corporation | Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity |
DE69919887T2 (de) | 1998-11-03 | 2005-09-15 | Glaxo Group Ltd., Greenford | Pyrazolopyridin derivative als selektive cox-2 inhibitoren |
US6025683A (en) | 1998-12-23 | 2000-02-15 | Stryker Corporation | Motor control circuit for regulating a D.C. motor |
AUPP873799A0 (en) | 1999-02-17 | 1999-03-11 | Fujisawa Pharmaceutical Co., Ltd. | Pyridine compounds |
WO2000052008A1 (fr) | 1999-02-27 | 2000-09-08 | Glaxo Group Limited | Pyrazolopyridines |
AU776831B2 (en) | 1999-09-14 | 2004-09-23 | Merck Frosst Canada Ltd. | Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
JP2001089452A (ja) | 1999-09-22 | 2001-04-03 | Sankyo Co Ltd | ピリミジン誘導体 |
US7345051B2 (en) | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
JP2005522477A (ja) | 2002-04-08 | 2005-07-28 | グラクソ グループ リミテッド | (2−((2−アルコキシ)−フェニル)−シクロペント−1−エニル)芳香族炭素環式および複素環式酸および誘導体 |
GB0212785D0 (en) | 2002-05-31 | 2002-07-10 | Glaxo Group Ltd | Compounds |
WO2004039807A1 (fr) | 2002-10-30 | 2004-05-13 | Merck Frosst Canada & Co. | Pyridopyrrolizine et derives de pyridoindolizine |
GB0225548D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Compounds |
GB0306329D0 (en) | 2003-03-19 | 2003-04-23 | Glaxo Group Ltd | Compounds |
GB0323584D0 (en) | 2003-10-08 | 2003-11-12 | Glaxo Group Ltd | Compounds |
GB0323581D0 (en) | 2003-10-08 | 2003-11-12 | Glaxo Group Ltd | Novel compounds |
GB0323585D0 (en) | 2003-10-08 | 2003-11-12 | Glaxo Group Ltd | Compounds |
JP2007509104A (ja) | 2003-10-24 | 2007-04-12 | グラクソ グループ リミテッド | 複素環式化合物 |
GB0328024D0 (en) | 2003-12-03 | 2004-01-07 | Glaxo Group Ltd | Compounds |
GB0410121D0 (en) | 2004-05-06 | 2004-06-09 | Glaxo Group Ltd | Compounds |
-
2005
- 2005-12-21 DE DE602005013116T patent/DE602005013116D1/de active Active
- 2005-12-21 ES ES05817767T patent/ES2321535T3/es active Active
- 2005-12-21 UY UY29298A patent/UY29298A1/es unknown
- 2005-12-21 BR BRPI0519398-2A patent/BRPI0519398A2/pt not_active IP Right Cessation
- 2005-12-21 EA EA200801909A patent/EA200801909A1/ru unknown
- 2005-12-21 CA CA002592442A patent/CA2592442A1/fr not_active Abandoned
- 2005-12-21 JP JP2007547393A patent/JP2008525363A/ja not_active Withdrawn
- 2005-12-21 EP EP05817767A patent/EP1833795B1/fr active Active
- 2005-12-21 US US11/722,402 patent/US20100137378A1/en not_active Abandoned
- 2005-12-21 AR ARP050105412A patent/AR052429A1/es unknown
- 2005-12-21 KR KR1020077014271A patent/KR20070091301A/ko not_active Application Discontinuation
- 2005-12-21 EA EA200701324A patent/EA200701324A1/ru unknown
- 2005-12-21 AT AT05817767T patent/ATE424386T1/de not_active IP Right Cessation
- 2005-12-21 AU AU2005318372A patent/AU2005318372A1/en not_active Abandoned
- 2005-12-21 WO PCT/EP2005/014061 patent/WO2006066968A1/fr active Application Filing
- 2005-12-21 MX MX2007007830A patent/MX2007007830A/es not_active Application Discontinuation
- 2005-12-21 EP EP09150218A patent/EP2053042A1/fr not_active Withdrawn
- 2005-12-21 TW TW094145424A patent/TW200640865A/zh unknown
-
2006
- 2006-01-03 PE PE2006000025A patent/PE20060838A1/es not_active Application Discontinuation
- 2006-01-30 PE PE2008001431A patent/PE20081440A1/es not_active Application Discontinuation
-
2007
- 2007-06-06 MA MA29966A patent/MA29082B1/fr unknown
- 2007-06-07 IL IL183781A patent/IL183781A0/en unknown
- 2007-06-21 US US11/766,418 patent/US7759369B2/en not_active Expired - Fee Related
- 2007-06-28 NO NO20073332A patent/NO20073332L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US7759369B2 (en) | 2010-07-20 |
MX2007007830A (es) | 2007-07-25 |
ES2321535T3 (es) | 2009-06-08 |
EA200701324A1 (ru) | 2007-10-26 |
EP1833795A1 (fr) | 2007-09-19 |
UY29298A1 (es) | 2006-05-31 |
DE602005013116D1 (de) | 2009-04-16 |
TW200640865A (en) | 2006-12-01 |
PE20081440A1 (es) | 2008-12-31 |
BRPI0519398A2 (pt) | 2009-01-20 |
EP1833795B1 (fr) | 2009-03-04 |
PE20060838A1 (es) | 2006-10-12 |
AU2005318372A1 (en) | 2006-06-29 |
NO20073332L (no) | 2007-09-17 |
AR052429A1 (es) | 2007-03-21 |
ATE424386T1 (de) | 2009-03-15 |
US20080249138A1 (en) | 2008-10-09 |
CA2592442A1 (fr) | 2006-06-29 |
WO2006066968A1 (fr) | 2006-06-29 |
KR20070091301A (ko) | 2007-09-10 |
EP2053042A1 (fr) | 2009-04-29 |
IL183781A0 (en) | 2007-09-20 |
US20100137378A1 (en) | 2010-06-03 |
JP2008525363A (ja) | 2008-07-17 |
EA200801909A1 (ru) | 2009-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29082B1 (fr) | Composes de pyridine destines au traitement de maladies a mediation par prostaglandine | |
GB0312832D0 (en) | 2-amino-pyridine derivatives useful for the treatment of diseases | |
LTC1830843I2 (lt) | Indolidono dariniai, skirti fibrozinių ligų gydymui arba prevencijai | |
IL164263A0 (en) | Use of ep4 receptor ligands on the treatment of il-6 involved diseases | |
AP2037A (en) | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases | |
PL376156A1 (en) | Pgd2 receptor antagonists for the treatment of inflammatory diseases | |
BR0304291B1 (pt) | absorvente higiÊnico. | |
ZA200608955B (en) | PGD2 receptor antagonists for the treatment of inflammatory diseases | |
EP1522314A4 (fr) | Remedes pour les maladies provoquees par la contraction ou la dilatation vasculaire | |
NO20053384L (no) | Benzazepinderivater for behandling av neurologiske forstyrrelser. | |
ZA200805839B (en) | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of Alzheimer's disease via GABA receptors | |
NO20053264D0 (no) | Innretning for produksjon av honningkakehonning. | |
NO20053623D0 (no) | Derivater av prostaglandiner for behandling av abdominalt ubehag | |
DE60305063D1 (de) | Ccr1-rezeptor-antagonisten zur behandlung u.a. demyelinisierender entzündlicher erkrankungen | |
HK1098155A1 (en) | Nicotinic receptor agonists for the treatment of inflammatory diseases | |
NL1024677A1 (nl) | Therapeutische prolinederivaten. | |
DE60315490D1 (de) | Therapeutische behandlung | |
ATE455540T1 (de) | Orale dosierform für die kontrollierte arzneimittelfreisetzung | |
GB0403370D0 (en) | Device for preventing retinal diseases | |
DK1474415T3 (da) | 1-phenyl-2-heteroaryl-substituerede benzimidazolderivater, deres anvendelse til fremstilling af lægemidler til behandling af immunologiske sygdomme | |
NL1028597A1 (nl) | Formamidederivaten voor de behandeling van ziekten. | |
ITMI20051661A1 (it) | Dispositivo di incenerimento particolarmente per la connessione dell'asse su apparecchi igienici | |
FR2863452B1 (fr) | Piquets de cloture associes par auto-assemblage | |
GB0312840D0 (en) | 2-amino-pyridine derivatives useful for the treatment of diseases | |
GB0312842D0 (en) | 2-amino-pyridine derivatives useful for the treatment of diseases |